Performance-Enhancing Drugs Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Performance-Enhancing Drugs Market Trends and Insights

Rising Demand for Performance Optimization in Competitive Sports and Fitness

The mainstream spread of testosterone replacement therapy is one of the clearest structural changes in the performance-enhancing drugs market. In July 2026, the US Department of Defense announced annual testosterone deficiency screening for all service members aged 30 and above, with optional access for younger personnel and treatment where deficiency is confirmed.^{[1]Marius Pharmaceuticals, “Marius Pharmaceuticals Welcomes Department of Defense's New Testosterone Screening Initiative for U.S. Service Members,” GlobeNewswire, globenewswire.com}That move shows that testosterone optimization is being treated more like a broader health protocol and less like a narrow edge-case intervention. In September 2025, Hims & Hers launched a dedicated men’s TRT category with exclusive access to KYZATREX, an FDA-approved oral testosterone product that restored testosterone levels in 96% of patients while avoiding injections.^{[2]Hims & Hers Health, “Hims Launches New Category in Men's Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments,” BusinessWire, businesswire.com} As telehealth lowers prescription friction, the performance-enhancing drugs market is seeing more clinical-grade anabolic steroid demand move through licensed channels instead of informal supply routes.

Expansion of Online and Cross-Border Supply Networks

Digital dispensing is becoming a stronger distribution backbone in the performance-enhancing drugs market, especially for products that are sold OTC or under lighter prescription controls. Redcare Pharmacy reported that its prescription drug revenue in Germany nearly doubled to EUR 503 million in 2025, while group Rx revenue rose 42.6% year over year to EUR 1.1 billion.^{[3]Redcare Pharmacy, “Strong Growth in 2025 Surpassing EUR 1bn in Rx Revenue, Adj. EBITDA Up 72% YoY,” Placera, placera.se} These figures show how quickly consumers are shifting from physical pharmacies to digital channels in regulated settings. The same convenience also supports cross-border gray-market activity, which remains a major force in the performance-enhancing drugs market. INTERPOL said Operation Pangea XVII dismantled 123 criminal groups operating across 90 countries and shut down around 13,000 criminal-linked websites, social media pages, and channels that marketed illicit products. This combination shows that legal online pharmacies and illicit digital sellers are competing for the same demand base.

Better Targeting Through Long-Acting, Safer, and More Selective Formulations

Formulation improvement is raising adherence and expanding legitimate use in the performance-enhancing drugs market. In July 2025, Ascendis Pharma received FDA approval for SKYTROFA for adults with growth hormone deficiency, introducing a once-weekly option that reduced the burden of daily injections. In February 2026, Novo Nordisk’s Sogroya became the first once-weekly long-acting growth hormone to gain 3 additional pediatric indications, which broadened the treated population further. These developments are strengthening the clinical footprint of HGH products inside the performance-enhancing drugs market. They also create spillover demand because easier dosing and more selective treatment profiles make these products more attractive outside of strictly medical use.

Rising Clinical Use in Hormonal and Muscle-Wasting Indications

The performance-enhancing drugs market is also drawing support from broader non-elite demand tied to physique goals, recovery, and mental performance. France’s Inserm reported in 2026 that anabolic steroid use among regular gym users in Western countries ranged from 10% to 35%, and the prevalence had been rising since 2022. Germany’s University of Erfurt found that 3.7% of adults were currently taking prescription drugs for cognitive performance without a medical indication, which equated to around 2.5 million users. These demand pools extend the performance-enhancing drugs market beyond conventional athletic use and create more repeat purchasing across hormone, stimulant, and peptide categories. They also feed both compliant and non-compliant channels at the same time, which makes demand expansion easier to see than channel quality.

Stringent Anti-Doping Enforcement and Prescription Controls

Anti-doping enforcement is scaling up in ways that directly affect the performance-enhancing drugs market. The International Testing Agency said it collected more than 44,400 samples from over 17,200 athletes across 216 countries in 2024, which was a 10% increase from 2023, and it managed 532 potential rule violations, with 232 leading to sanctions. India also remained a major testing market, with 7,113 tests and 260 adverse analytical findings in 2024 before the positivity rate fell to 1.5% across 7,068 tests in 2025 after stronger education and monitoring efforts. The bigger commercial issue is that newer peptides and SARMs are being added or reclassified on prohibited lists, which narrows the gray area where many compounds have been marketed. That trend raises legal risk, limits open distribution, and forces the performance-enhancing drugs market to favor approved therapies over loosely positioned products.

Counterfeit and Substandard Product Penetration

Counterfeit supply remains one of the most disruptive restraints in the performance-enhancing drugs market. US Customs and Border Protection intercepted 71 shipments of counterfeit HGH during a 6-day operation across 5 ports of entry in March 2025, and the agency also noted a sharp rise in precursor chemical interceptions in mail, express consignment, and air cargo environments. In Europe, SHIELD VI coordinated enforcement across 30 countries and seized 4.6 million performance-enhancing substance tablets and 1.2 million vials and ampoules valued at EUR 33.2 million, or USD 36.3 million. These volumes show that illicit sellers are not a side issue but a parallel supply structure inside the performance-enhancing drugs market. Counterfeit products pressure legitimate pricing, increase health risks, and trigger tighter scrutiny that raises operating costs for compliant manufacturers and distributors.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug Type: Anabolic Steroid Dominance Challenged by Long-Acting Peptide Pipeline

Anabolic steroids held 39.34% of the performance-enhancing drugs market share in 2025. Their lead reflected decades of established use in testosterone replacement therapy and muscle-wasting conditions. The category also benefited from a broad generic manufacturing base, which supported supply across both prescription and gray-market channels. In the performance-enhancing drugs industry, stimulants remained the second-largest segment, while beta-blockers and diuretics served narrower use cases linked to cognitive performance, weight control, and precision or weight-class sports.

The performance-enhancing drugs market for human growth hormone and peptides is projected to expand at a 9.55% CAGR through 2031. Once-weekly HGH products are widening legitimate clinical access, which strengthens the reference demand that supports this category. The July 2025 FDA approval of SKYTROFA for adults with growth hormone deficiency widened adult treatment access.

By Route of Administration: Parenteral Growth Driven by Clinical Protocol Shifts

The oral route commanded a 38.52% share in 2025, which reflected enduring consumer preference for convenience. Oral formats fit both prescription and OTC demand in the performance-enhancing drugs market and remain easier to distribute across retail and digital settings. Topical and transdermal routes also remain relevant where users want needle-free administration and steady hormone delivery. These formats help preserve adherence in long-cycle therapy and broaden access for users who avoid injections.

The performance-enhancing drugs market for parenteral administration is projected to grow at an 8.17% CAGR through 2031. Injectable formats are gaining relevance because they offer precise dosing, strong bioavailability, and easier integration into medically supervised micro-dosing protocols. The performance-enhancing drugs market is also seeing more regulatory support for injectable testosterone formats, which strengthens the clinical role of parenteral use. In the United States, Schedule III controls create a barrier that keeps a large share of compliant injectable demand inside hospital and licensed retail pharmacy channels.

By Dosage Form: Injections Overtake Pills in Growth Trajectory

Pills and supplements retained a 40.33% share in 2025, which kept them as the most accessible dosage form in the performance-enhancing drugs market. They remained the default entry point for both supervised use and self-directed use because they are widely available and easier to consume. Oral liquids and topical creams formed smaller categories, but they still served patients and users who preferred easier administration. Customized hormone creams also stayed relevant through specialty dispensing and compounding channels.

The performance-enhancing drugs market for injections is expected to advance at an 7.76% CAGR through 2031. Therapeutic users and performance-oriented users are both moving toward injectable formats when they want higher bioavailability and more controlled delivery. Clinical guidance also supports this pattern, because testosterone replacement criteria continue to caution against certain oral forms and support use in clinically appropriate dosing frameworks. Patches remain a niche option, but formulation-specific detection windows and practical use patterns still influence demand across the performance-enhancing drugs market.

By Application: Anti-Aging and Wellness Structurally Outpacing Sports

Athletic performance accounted for 42.10% of demand in 2025, which kept it as the largest application in the performance-enhancing drugs market. That position reflected the long historical link between performance enhancement and both competitive and recreational sport. Bodybuilding and muscle enhancement remained another large use case, supported by persistent physique-oriented demand across gym culture.

The performance-enhancing drugs market for anti-aging and wellness is anticipated to expand at a 9.12% CAGR through 2031. Aging consumers are increasingly engaging with HGH, testosterone, and peptide therapies through telehealth platforms and longevity-focused clinics. Cognitive enhancement is also emerging as a meaningful adjacent use case in the performance-enhancing drugs market.

By Distribution Channel: Online Pharmacy Growth Reshaping Access

Hospital pharmacies held 44.41% in 2025 and remained the anchor channel for the performance-enhancing drugs market. Their lead came from clinically supervised testosterone replacement, HGH treatment, and other physician-managed hormonal therapies. Prescription controls for anabolic steroids in the United States continue to funnel compliant volume through institutional dispensing. Retail pharmacies also remain important where chronic therapy users rely on generic preparations and regular refill behavior.

Online pharmacies are expected to record the fastest growth at a 8.52% CAGR through 2031. Redcare’s German prescription revenue nearly doubled to EUR 503 million in 2025, which shows how digital dispensing is gaining traction in regulated environments. At the same time, illicit websites remain a major threat, and that keeps channel trust and verification central to competition in the performance-enhancing drugs market.

Geography Analysis

North America accounted for 46.23% of the performance-enhancing drugs market share in 2025. The region leads because the United States has an established testosterone replacement therapy base, a large number of licensed dispensing channels, and stronger telehealth participation. The July 2026 Department of Defense screening initiative adds another layer of institutional demand by treating testosterone deficiency as a broader health issue. Canada is also gaining importance in the performance-enhancing drugs market, and Hikma’s May 2026 licensing agreement for KYZATREX shows that multinational companies view it as a structured extension of the North American therapy base.

Europe remained the second-largest regional footprint in the performance-enhancing drugs market. The region combines deep prescription infrastructure with stronger cross-border oversight, which makes it both commercially attractive and operationally demanding. OLAF’s SHIELD V operation in January 2025 seized more than 3.4 million pills, including anabolic steroids and doping substances, across EU member states. France’s 2026 Inserm review also pointed to rising anabolic steroid use among gym populations, which suggests that non-elite demand remains active even under tighter surveillance.

Asia-Pacific is projected to grow fastest at a 10.13% CAGR through 2031, making it the performance-enhancing drugs market size leader in growth terms. The region benefits from rising disposable income, stronger supplement acceptance, and a younger consumer base that is heavily influenced by social media and appearance-led fitness behavior. India shows both the demand side and the enforcement side of the performance-enhancing drugs market, with 260 adverse analytical findings from 7,113 tests in 2024, before the positivity rate fell sharply in 2025. Japan and South Korea remain more compliance-led markets, while parts of Southeast Asia are emerging as broader volume channels. In the Middle East and Africa, wealthy GCC consumers and South Africa’s sports base support demand, while Brazil remains the key South American market because bodybuilding culture and local pharmaceutical capacity continue to support the wider performance-enhancing drugs market.